5th Annual Next Gen Microbiome and Probiotics Conference: Connect with Biotech, Pharma, Academicians and Investors (San Diego, United States – February 8-9, 2023) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “5th Annual Next Gen Microbiome and Probiotics Conference” has been added to ResearchAndMarkets.com’s offering.

Connect with biotech, pharma, academicians and investors at 5th Annual Next Gen Microbiome and Probiotics Conference on 8th – 9th February 2023 in San Diego, USA, discussing the most ingenious research and technological advances.

Key sessions on effective microbiome therapeutics in production, regulatory pathways, prebiotics, probiotics and postbiotics, along with discussion on effective translation from R&D to commercialization.

The ecology of the human microbiome is known to be associated with both phenotype and environment. With the increasing focus on the development of human microbiome therapies and probiotics product & drug development various small innovative players are operating in the market.

However, inadequate research and regulatory policies in the human microbiome are some of the factors which restrain the progress. Learn about microbial innovation and applying the new microbiome findings along with the regulatory pathways for better therapeutic development. Also, witness discussions on microbiome vs probiotics and the link between them.

What To Expect

Key Highlights

• Effective Microbiome Therapeutics in Production
• Role of the human skin microbiome in precision health
• The increasing pro-bacterial beauty industry
• Business collaborations- Regulations and Investments
• Microbiome as a science and its clinical applications- skin, gut & women’s health
• Regulatory pathways
• Prebiotics, Probiotics and Postbiotics
• R&D to commercialization- effectively translating research into commercialization
• Rightly educating the consumer

Who Should Attend:

Medical Directors, Principal Investigators, Methodologists, and other clinical research professionals from pharmaceuticals, nutraceuticals and therapeutics-based organizations from the departments of:

• Microbiome discovery
• Department of Biochemistry and Immunology
• Microbiome science
• Microbiology
• Biological Science
• Gut Biology
• Human microbiome
• Drug discovery
• Therapeutics
• Immunotherapy

Directors, Heads, Professors/Assistant Professors/ Associate Professor, Research Scholars, Scientists from the departments of:

• Microbiology
• Microbiome therapeutics
• Microbiome
• Gastroenterology
• Immunology
• Bioinformatics
• Obstetrics
• Neonatology
• Functional foods
• Pediatrics
• Nutritionists/dieticians
• Gut inflammation
• Mucosal immunity
• Immunopharmacology Group
• Gut disgiosis
• Skin conditions
• Baterria and excema gut and bacteria
• Infant and gut
• Pediatric and git
• Gut brain axis

Agenda:

Day 1 Wed, 08-Feb-2023

• Registration
• 08:15 – 08:55: Welcome note
• 08:55 – 09:00: Opening Remarks from the Chairperson
• 09:00 – 09:10: Keynote Presentation- Microbiome in true sense- Is it a biomarker or is it a therapy?
• 09:10 – 09:40: New insights in gut brain axis
• 09:40 – 10:10: Solution Provider Presentation
• 10:10 – 10:25: Morning Refreshments and Poster Presentation – One-to-One Networking Meetings
• 10:25 – 11:10: Standardizing microbiome measurements-Which regulatory body should be approached?
• 11:10 – 11:40: Solution Provider Presentation
• 11:40 – 12:10: Lifecyle of prebiotics, probiotics and post-biotics and importance of balance of all three
• 12:10 – 12:40: Educating the consumer- rightly simplifying the dynamics of microbiome products
• 12:40 – 13:10: Lunch and Poster Presentation – One-to-One Networking Meetings
• 13:10 – 14:10: Panel Discussion- Differences between microbiome therapeutics at different body sites
• 14:10 – 14:40: Regulatory standards for probiotics
• 14:40 – 14:55: Gut Inflammation- what responses do we have to manage the gut inflammation that drives the intestinal disorders and systemic disease
• 14:55 – 15:25: Strain Identification: A systematic approach to characterize the effectiveness and safety of novel probiotic strains with the help of latest technologies
• 15:25 – 15:55: Afternoon Refreshments and Poster Presentation – One-to-One Networking Meetings
• 15:55 – 16:40: Role of human skin microbiome in precision health
• 16:40 – 17:10: GAP funding – The biggest funding hurdle
• 17:10 – 17:40: Closing Remarks from the Chairperson
• 17:40 – 17:45: Drinks Reception & Networking
• 17:45 – 17:45: End of Day 1

Day 2 Thu, 09-Feb-2023

• Registration
• 08:15 – 08:55: Welcome note
• 08:55 – 09:00: Opening Remarks from the Chairperson
• 09:00 – 09:10: Back to basics- Less is more, learning to use the right product for microbiome health
• 09:10 – 09:40: Applications of microbiome in other arenas
• 09:40 – 10:10: Solution Provider Presentation
• 10:10 – 10:25: Morning Refreshments and Poster Presentation – One-to-One Networking Meetings
• 10:25 – 11:10: Pediatric and infant health- How to prevent a child from eczema soon after the birth
• 11:10 – 11:40: Solution Provider Presentation
• 11:40 – 12:10: Long brain axis
• 12:10 – 12:40: Hurdles to market translation- Effectively distilling down the complexities of product uses to the average consumers and veterans
• 12:40 – 13:10: Lunch and Poster Presentation – One-to-One Networking Meetings
• 13:10 – 14:10: Next-Generation Probiotics: Modulating Gut Microbiota for Health & Wellness
• 14:10 – 14:40: Next-Generation Probiotics: Modulating Gut Microbiota for Health & Wellness
• 14:40 – 15:10: Technology transfer- Moving the research out of the university into a business
• 15:10 – 15:40: Closing Remarks from the Chairman
• 15:40 – 15:45: End of Conference

Speakers

Julius Goepp

Founder, CEO, Scaled Microbiomics

Maya Ivanjesku

Chief Scientific Officer, Dakota Biotech

Peter Leighton

CEO, ProSperity Bioscience

Seth D. Crosby

Director, Research Collaborations, Washington University School of Medicine

Arun K. Bhunia

Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease

Emily Stein

CEO, Primal Health Inc.

Nicole M. Scott

CEO and Founder, Cybele Microbiome

Yug Varma

CEO, Phi Therapeutics

Larry Weiss

CEO & Founder, Symbiome

Leigh A. Frame

Associate Director, Resiliency & Well-being Center, Program Director, Integrative Medicine (INTM), Executive Director, Office of INTM & Health

Scott A. Jackson

Leader – Complex Microbial Systems Group, NIST – National Institute of Standards and Technology

Andrea Azcarate-Peril

Associate Professor of Medicine, Director, UNC Microbiome Core, School of Medicine, University of North Carolina at Chapel Hill

For more information about this conference visit https://www.researchandmarkets.com/r/hihahn

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900